Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
Identifieur interne : 001396 ( PubMed/Checkpoint ); précédent : 001395; suivant : 001397Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
Auteurs : A. Bilang-Bleuel [France] ; F. Revah ; P. Colin ; I. Locquet ; J J Robert ; J. Mallet ; P. HorellouSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1997.
English descriptors
- KwdEn :
- Adenoviridae, Animals, Behavior, Animal (drug effects), Disease Models, Animal, Female, Gene Transfer Techniques, Genetic Therapy, Genetic Vectors, Glial Cell Line-Derived Neurotrophic Factor, Nerve Growth Factors, Nerve Tissue Proteins (administration & dosage), Nerve Tissue Proteins (genetics), Neurons (drug effects), Neurons (pathology), Neuroprotective Agents (administration & dosage), Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson Disease (pathology), Rats, Rats, Sprague-Dawley.
- MESH :
- chemical , administration & dosage : Nerve Tissue Proteins, Neuroprotective Agents.
- chemical , genetics : Nerve Tissue Proteins.
- chemical : Glial Cell Line-Derived Neurotrophic Factor, Nerve Growth Factors.
- drug effects : Behavior, Animal, Neurons.
- drug therapy : Parkinson Disease.
- genetics : Parkinson Disease.
- metabolism : Parkinson Disease.
- pathology : Neurons, Parkinson Disease.
- Adenoviridae, Animals, Disease Models, Animal, Female, Gene Transfer Techniques, Genetic Therapy, Genetic Vectors, Rats, Rats, Sprague-Dawley.
Abstract
Glial-cell-line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor for adult nigral dopamine neurons in vivo. GDNF has both protective and restorative effects on the nigro-striatal dopaminergic (DA) system in animal models of Parkinson disease. Appropriate administration of this factor is essential for the success of its clinical application. Since it cannot cross the blood-brain barrier, a gene transfer method may be appropriate for delivery of the trophic factor to DA cells. We have constructed a recombinant adenovirus (Ad) encoding GDNF and injected it into rat striatum to make use of its ability to infect neurons and to be retrogradely transported by DA neurons. Ad-GDNF was found to drive production of large amounts of GDNF, as quantified by ELISA. The GDNF produced after gene transfer was biologically active: it increased the survival and differentiation of DA neurons in vitro. To test the efficacy of the Ad-mediated GDNF gene transfer in vivo, we used a progressive lesion model of Parkinson disease. Rats received injections unilaterally into their striatum first of Ad and then 6 days later of 6-hydroxydopamine. We found that mesencephalic nigral dopamine neurons of animals treated with the Ad-GDNF were protected, whereas those of animals treated with the Ad-beta-galactosidase were not. This protection was associated with a difference in motor function: amphetamine-induced turning was much lower in animals that received the Ad-GDNF than in the animals that received Ad-beta-galactosidase. This finding may have implications for the development of a treatment for Parkinson disease based on the use of neurotrophic factors.
PubMed: 9238061
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9238061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.</title><author><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name><affiliation wicri:level="3"><nlm:affiliation>Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Revah, F" sort="Revah, F" uniqKey="Revah F" first="F" last="Revah">F. Revah</name></author><author><name sortKey="Colin, P" sort="Colin, P" uniqKey="Colin P" first="P" last="Colin">P. Colin</name></author><author><name sortKey="Locquet, I" sort="Locquet, I" uniqKey="Locquet I" first="I" last="Locquet">I. Locquet</name></author><author><name sortKey="Robert, J J" sort="Robert, J J" uniqKey="Robert J" first="J J" last="Robert">J J Robert</name></author><author><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name></author><author><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9238061</idno><idno type="pmid">9238061</idno><idno type="wicri:Area/PubMed/Corpus">001518</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001518</idno><idno type="wicri:Area/PubMed/Curation">001477</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001477</idno><idno type="wicri:Area/PubMed/Checkpoint">001477</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001477</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.</title><author><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name><affiliation wicri:level="3"><nlm:affiliation>Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Revah, F" sort="Revah, F" uniqKey="Revah F" first="F" last="Revah">F. Revah</name></author><author><name sortKey="Colin, P" sort="Colin, P" uniqKey="Colin P" first="P" last="Colin">P. Colin</name></author><author><name sortKey="Locquet, I" sort="Locquet, I" uniqKey="Locquet I" first="I" last="Locquet">I. Locquet</name></author><author><name sortKey="Robert, J J" sort="Robert, J J" uniqKey="Robert J" first="J J" last="Robert">J J Robert</name></author><author><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name></author><author><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae</term><term>Animals</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Female</term><term>Gene Transfer Techniques</term><term>Genetic Therapy</term><term>Genetic Vectors</term><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Nerve Growth Factors</term><term>Nerve Tissue Proteins (administration & dosage)</term><term>Nerve Tissue Proteins (genetics)</term><term>Neurons (drug effects)</term><term>Neurons (pathology)</term><term>Neuroprotective Agents (administration & dosage)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nerve Tissue Proteins</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Glial Cell Line-Derived Neurotrophic Factor</term><term>Nerve Growth Factors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neurons</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adenoviridae</term><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Gene Transfer Techniques</term><term>Genetic Therapy</term><term>Genetic Vectors</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glial-cell-line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor for adult nigral dopamine neurons in vivo. GDNF has both protective and restorative effects on the nigro-striatal dopaminergic (DA) system in animal models of Parkinson disease. Appropriate administration of this factor is essential for the success of its clinical application. Since it cannot cross the blood-brain barrier, a gene transfer method may be appropriate for delivery of the trophic factor to DA cells. We have constructed a recombinant adenovirus (Ad) encoding GDNF and injected it into rat striatum to make use of its ability to infect neurons and to be retrogradely transported by DA neurons. Ad-GDNF was found to drive production of large amounts of GDNF, as quantified by ELISA. The GDNF produced after gene transfer was biologically active: it increased the survival and differentiation of DA neurons in vitro. To test the efficacy of the Ad-mediated GDNF gene transfer in vivo, we used a progressive lesion model of Parkinson disease. Rats received injections unilaterally into their striatum first of Ad and then 6 days later of 6-hydroxydopamine. We found that mesencephalic nigral dopamine neurons of animals treated with the Ad-GDNF were protected, whereas those of animals treated with the Ad-beta-galactosidase were not. This protection was associated with a difference in motor function: amphetamine-induced turning was much lower in animals that received the Ad-GDNF than in the animals that received Ad-beta-galactosidase. This finding may have implications for the development of a treatment for Parkinson disease based on the use of neurotrophic factors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9238061</PMID><DateCreated><Year>1997</Year><Month>09</Month><Day>08</Day></DateCreated><DateCompleted><Year>1997</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>94</Volume><Issue>16</Issue><PubDate><Year>1997</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>8818-23</MedlinePgn></Pagination><Abstract><AbstractText>Glial-cell-line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor for adult nigral dopamine neurons in vivo. GDNF has both protective and restorative effects on the nigro-striatal dopaminergic (DA) system in animal models of Parkinson disease. Appropriate administration of this factor is essential for the success of its clinical application. Since it cannot cross the blood-brain barrier, a gene transfer method may be appropriate for delivery of the trophic factor to DA cells. We have constructed a recombinant adenovirus (Ad) encoding GDNF and injected it into rat striatum to make use of its ability to infect neurons and to be retrogradely transported by DA neurons. Ad-GDNF was found to drive production of large amounts of GDNF, as quantified by ELISA. The GDNF produced after gene transfer was biologically active: it increased the survival and differentiation of DA neurons in vitro. To test the efficacy of the Ad-mediated GDNF gene transfer in vivo, we used a progressive lesion model of Parkinson disease. Rats received injections unilaterally into their striatum first of Ad and then 6 days later of 6-hydroxydopamine. We found that mesencephalic nigral dopamine neurons of animals treated with the Ad-GDNF were protected, whereas those of animals treated with the Ad-beta-galactosidase were not. This protection was associated with a difference in motor function: amphetamine-induced turning was much lower in animals that received the Ad-GDNF than in the animals that received Ad-beta-galactosidase. This finding may have implications for the development of a treatment for Parkinson disease based on the use of neurotrophic factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilang-Bleuel</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité Mixte de Recherche 9923, Centre National de la Recherche Scientifique, Hôpital de la Pitié-Salpêtrière, Bâtiment CERVI, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revah</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Colin</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Locquet</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Mallet</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Horellou</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495041">Gdnf protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1970 Dec 18;24(3):485-93</RefSource><PMID Version="1">5494536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1997 Feb 7;275(5301):838-41</RefSource><PMID Version="1">9012352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1980 Aug 11;195(1):123-37</RefSource><PMID Version="1">6105003</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 1984 Jan 25;12(2):857-72</RefSource><PMID Version="1">6694911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1992 Aug;90(2):626-30</RefSource><PMID Version="1">1644927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1993 Feb 12;259(5097):988-90</RefSource><PMID Version="1">8382374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1993 May 21;260(5111):1130-2</RefSource><PMID Version="1">8493557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1993 Oct 29;626(1-2):167-74</RefSource><PMID Version="1">8281427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 1993 Dec;124(2):368-71</RefSource><PMID Version="1">8287932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1994 Mar;59(2):401-15</RefSource><PMID Version="1">7516500</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1994 Aug;63(2):758-68</RefSource><PMID Version="1">8035200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1994 Jun 13;648(1):171-5</RefSource><PMID Version="1">7922521</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1995 Jan 26;373(6512):335-9</RefSource><PMID Version="1">7830766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1995 Jan 26;373(6512):339-41</RefSource><PMID Version="1">7830767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 1994 Dec 30;6(1):49-53</RefSource><PMID Version="1">7703427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 1995 Mar;9(3):256-60</RefSource><PMID Version="1">7773288</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8274-8</RefSource><PMID Version="1">7667281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8935-9</RefSource><PMID Version="1">7568047</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 1996 Jan;70(1):559-65</RefSource><PMID Version="1">8523570</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1996 Jan;66(1):74-82</RefSource><PMID Version="1">8522992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1996 May 1;16(9):3045-55</RefSource><PMID Version="1">8622134</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1996 Mar 21;380(6571):252-5</RefSource><PMID Version="1">8637574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 1996 May;139(1):39-53</RefSource><PMID Version="1">8635567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 1996 Sep;111(1):1-7</RefSource><PMID Version="1">8891630</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1996 Nov 15;16(22):7206-15</RefSource><PMID Version="1">8929429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1979 Nov 30;177(3):555-60</RefSource><PMID Version="1">574053</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="Y">Nerve Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC23145</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9238061</ArticleId><ArticleId IdType="pmc">PMC23145</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Colin, P" sort="Colin, P" uniqKey="Colin P" first="P" last="Colin">P. Colin</name><name sortKey="Horellou, P" sort="Horellou, P" uniqKey="Horellou P" first="P" last="Horellou">P. Horellou</name><name sortKey="Locquet, I" sort="Locquet, I" uniqKey="Locquet I" first="I" last="Locquet">I. Locquet</name><name sortKey="Mallet, J" sort="Mallet, J" uniqKey="Mallet J" first="J" last="Mallet">J. Mallet</name><name sortKey="Revah, F" sort="Revah, F" uniqKey="Revah F" first="F" last="Revah">F. Revah</name><name sortKey="Robert, J J" sort="Robert, J J" uniqKey="Robert J" first="J J" last="Robert">J J Robert</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Bilang Bleuel, A" sort="Bilang Bleuel, A" uniqKey="Bilang Bleuel A" first="A" last="Bilang-Bleuel">A. Bilang-Bleuel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001396 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001396 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9238061
|texte= Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9238061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |